In what is generally an age of skepticism about the prospects for biotech companies, the valuation prizes generally go to companies close to profits.
And no biotech group seems further from profitability than the genomics companies. As Incyte Pharmaceuticals Inc. CFO Denise Gilbert, PhD,...
Welcome to In Vivo
Create an account to read this article
Already a subscriber?